The Fly | GLMD

Addressing Significant Unmet Need: Aramchol targets MASH (formerly NASH), a prevalent liver disease with no approved pharmacological therapies, positioning Galmed at the forefront of a high-demand therapeutic area.

Unique Mechanism of Action (MOA): Aramchol acts as a liver-targeted Stearoyl-CoA Desaturase 1 (SCD1) modulator, offering a novel and differentiated therapeutic approach compared to other investigational drugs for MASH.

Demonstrated Anti-fibrotic Efficacy: Clinical trials have shown Aramchol's ability to reduce liver fat and, significantly, improve liver fibrosis without worsening MASH, a critical endpoint for patients with advanced disease.

Clinical Trial Failure Risk: The company's lead product, Aramchol, may fail to demonstrate efficacy or safety in ongoing or future clinical trials.

Regulatory Approval Uncertainty: Even if clinical trials are successful, there is no guarantee that Aramchol will receive necessary regulatory approvals from health authorities.

Significant Funding Requirements: Galmed will require substantial additional capital to complete clinical development, pursue regulatory approvals, and commercialize Aramchol.

Charts

Clinical Trial Failure Risk: The company's lead product, Aramchol, may fail to demonstrate efficacy or safety in ongoing or future clinical trials.

Regulatory Approval Uncertainty: Even if clinical trials are successful, there is no guarantee that Aramchol will receive necessary regulatory approvals from health authorities.

Significant Funding Requirements: Galmed will require substantial additional capital to complete clinical development, pursue regulatory approvals, and commercialize Aramchol.

Today

Galmed announces development of novel LNP cardiac targeted Aramchol formulation